NCT06498518 2025-07-11
PRIMUS006
University of Glasgow
Phase 2 Withdrawn
Clinical Trials
16 trialsNCT05518032 2024-09-26
Pembrolizumab and Autologous Dendritic Cells for the Treatment of Refractory Colorectal Cancer (CRC)
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT04231526 2024-07-31
Pembrolizumab in Early Stage Colon Cancer
University of Chicago
Phase 2 Withdrawn
NCT05431582 2023-06-15
Phase I Study of ZN-c3 and Bevacizumab ± Pembrolizumab in Metastatic CCNE1 Amplified and TP53 Mutant Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT03592407 2022-03-08
Epacadostat and Pembrolizumab Before Surgery in Treating Participants With Stage II-III Esophageal or Gastroesophageal Cancer
City of Hope Medical Center
Phase 2 Withdrawn
NCT04119830 2022-02-08
Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 2 Withdrawn
NCT04859582 2021-12-16
KEYNOTE-859
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT04536922 2021-02-01
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated or Viral Neoantigens in a Patient With Metastatic Cancer Plus the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Withdrawn
NCT03891979 2020-06-26
Gut Microbiome Modulation to Enable Efficacy of Checkpoint-based Immunotherapy in Pancreatic Adenocarcinoma
NYU Langone Health
Phase 4 Withdrawn
NCT04058964 2020-03-13
Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT04158700 2020-02-19
A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1/2 Withdrawn
NCT03881111 2020-02-11
KEYNOTE-590
Merck Sharp & Dohme LLC
Phase 3 Withdrawn
NCT03432676 2019-05-30
Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT03182894 2018-08-28
Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer
University of Pittsburgh
Phase 1/2 Withdrawn
NCT02943603 2018-07-13
A Study of Perioperative mFOLFOX6 Plus Pembrolizumab in Patients With Potentially Resectable Adenocarcinoma of the Gastroesophageal Junction (GEJ) and Stomach
University of Pittsburgh
Phase 2 Withdrawn
NCT02586610 2017-01-20
Trial of Chemoradiation and Pembrolizumab in Patients With Rectal Cancer
Hoosier Cancer Research Network
Phase 2 Withdrawn